| Serial Number | 98432248 |
| Word Mark | TETRAVECTA |
| Filing Date | Monday, March 4, 2024 |
| Status | 651 - SUSPENSION INQUIRY - MAILED |
| Status Date | Tuesday, September 9, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Custom manufacture of products relating to biotechnology, namely, custom manufacture of cell and gene therapies; custom manufacture of gene and cell-based therapy products, namely, cell and gene therapies, genetically engineered viral vectors, genetically engineered retroviral vectors, genetically engineered lentiviral vectors, genetically engineered adeno-associated viral vectors, genetically engineered adenoviral vectors, and non-vector preparations in the nature of cell and gene therapies, and biopharmaceutical preparations; biotechnology contract manufacturing services, namely, contract manufacturing in the field of cell and gene therapy using biological organisms; contract manufacturing services of gene and cell-based therapy products, namely, cell and gene therapies, genetically engineered viral vectors, genetically engineered retroviral vectors, genetically engineered lentiviral vectors, genetically engineered adeno-associated viral vectors, genetically engineered adenoviral vectors, and non-vector preparations in the nature of cell and gene therapies and biopharmaceutical products, namely, cell and gene therapies; contract manufacturing services of technology for biopharmaceutical products and gene and cell-based products, namely, custom manufacture of cell and gene therapies; contract manufacturing services of technology for viral vectors, retroviral vectors, lentiviral vectors, adeno-associated viral vectors, adenoviral vectors, and non-vector preparations, namely, custom manufacture of cell and gene therapies |
| Goods and Services | Research and laboratory analytic and diagnostic services, namely, scientific research, biochemical research, research laboratory analysis services in the field of gene therapy and biochemistry; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; product, viral vector product and analytic assay product development for others; laboratory services, namely, scientific laboratory services and biological research laboratory services; research and development services, namely, gene therapy research; genetic engineering laboratories, namely, scientific research in the field of genetic engineering provided in genetic engineering laboratories and biochemistry laboratories providing research and development in the field of biochemistry; scientific and technological services and research, namely, scientific research, analysis, testing in the fields of gene therapy and biochemistry; industrial analysis services, namely, providing analysis services with respect to gene-therapy based product manufacturing for industrial purposes; provision of information relating to scientific research; provision of scientific information in the fields of gene therapy and biochemistry; product research and scientific analysis of cell and gene therapies relating to drug discovery and product development for others; scientific advisory services relating to biochemistry; scientific consultancy services relating to biochemistry; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, March 4, 2024 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, March 4, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Oxford BioMedica Plc |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Oxford OX46LT GB |
| Event Date | Event Description |
| Monday, March 4, 2024 | NEW APPLICATION ENTERED |
| Monday, July 15, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, September 18, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, September 25, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, September 25, 2024 | NON-FINAL ACTION E-MAILED |
| Monday, December 23, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, December 24, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, January 21, 2025 | LETTER OF SUSPENSION E-MAILED |
| Tuesday, January 21, 2025 | SUSPENSION LETTER WRITTEN |
| Tuesday, January 21, 2025 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Tuesday, July 22, 2025 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Tuesday, September 9, 2025 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Tuesday, September 9, 2025 | SUSPENSION INQUIRY WRITTEN |
| Tuesday, September 9, 2025 | INQUIRY TO SUSPENSION E-MAILED |
| Wednesday, September 25, 2024 | NON-FINAL ACTION WRITTEN |
| Monday, December 23, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |